Compare Ishares Msci Italy ETF (EWI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Recursion Pharmaceuticals Inc — how do they compare? Ishares Msci Italy ETF trades at $63.25, while Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B). The key difference: Ishares Msci Italy ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EWI | RXRX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $6.79 |
52-Week Low | $50.31 | $2.84 |
Market Cap | — | $1.78B |
Enterprise Value | — | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, a US-listed stock, trades at $63.35, up 0.3% on the day, with technical indicators showing a bullish moving average trend but overbought oscillators. The stock recently hit a 52-week high, reflecting strong momentum. A dividend of $1.17 is scheduled for payment in June 2026, offering income potential. Recent news highlights European market strength and ECB policy impacts, which may influence EWI's performance given its European exposure.
The outlook for EWI is cautiously optimistic, driven by technical strength and positive European equity trends. Risks include potential ECB rate hikes and geopolitical tensions affecting energy costs. Analyst sentiment is mixed, with the stock near highs suggesting limited upside without new catalysts. Investors should weigh technical overbought signals against fundamental growth prospects.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
